New York residents who suffer from type 1 or type 2 diabetes run the risk of developing chronic kidney disease. Doctors generally study the estimated glomerular filtration rate and the urinary albumin to creatinine ratio to identify diabetes sufferers with high risks of developing these conditions, but doctors have long known that these two biomarkers are not always able to identify at-risk patients and often fail to accurately predict the onset of kidney failure.
In 2012, researchers at the Massachusetts-based Joslin Diabetes Center discovered a link between declining kidney function in type 1 and type 2 diabetes sufferers and the membrane receptor tumor necrosis factor receptor 1. The research center has now announced that it has developed a new prognostic test based on the discovery. During clinical studies, the new TNFR1 test was able to identify at-risk patients 71 percent of the time and predict the onset of ESRD within three years 81 percent of the time.
In addition to possibly saving the lives of type 1 and type 2 diabetes sufferers, the new test could also be used to select more appropriate candidates for clinical trials. About 80 percent of the patients currently enrolled in such trials provide doctors with little or no useful information according to the doctor who led the effort to develop the TNFR1 test.
Thousands of Americans lose their lives each year because their doctors failed to diagnose serious medical conditions. Chronic diseases sometimes go undetected because the prognostic tools used to identify them are ineffective, but many patients suffer unnecessarily because their doctors failed to order the appropriate tests or did not properly assess the results of the tests that were run. In these situations, personal injury attorneys with experience in cases involving negligent medical treatment could initiate litigation on behalf of patients who have been harmed as a result
Source: The Joslin Diabetes Center, New Test Identifies Patients with Diabetes Who Are At High Risk of Kidney Failure, News release, April 18, 2017